Ninety One (UK)
ALXN

Ninety One (UK)’s Alexion Pharmaceuticals ALXN Stock Holding History

Ninety One (UK)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-415,302
Closed -$46.6M – 244
2020
Q2 		$46.6M Sell
415,302
-1,353,569
-77% -$144M 0.17% 103
2020
Q1 		$159M Sell
1,768,871
-176,515
-9% -$17.3M 0.67% 44
2019
Q4 		$210M Sell
1,945,386
-58,896
-3% -$6.3M 0.7% 45
2019
Q3 		$196M Buy
2,004,282
+1,355,775
+209% +$153M 0.76% 38
2019
Q2 		$221M Sell
648,507
-1,024,997
-61% -$132M 0.84% 36
2019
Q1 		$226M Buy
1,673,504
+240,014
+17% +$29.8M 0.9% 28
2018
Q4 		$140M Buy
1,433,490
+66,288
+5% +$7.84M 0.6% 58
2018
Q3 		$190M Buy
1,367,202
+818,204
+149% +$103M 0.71% 47
2018
Q2 		$68.2M Buy
548,998
+82,961
+18% +$9.7M 0.34% 84
2018
Q1 		$51.9M Sell
466,037
-237,166
-34% -$28.3M 0.28% 89
2017
Q4 		$84.1M Buy
+703,203
New +$85.6M 0.35% 77

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ninety One (UK)'s ALXN Position: Q3 2020 in Review

Ninety One (UK) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 415,302 shares — an estimated $46.6M sold.

Ninety One (UK) first reported a position in ALXN in Q4 2017 and held it in 11 quarters. The position peaked at $226M in Q1 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Ninety One (UK) reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Ninety One (UK) sold 415,302 Alexion Pharmaceuticals shares in Q3 2020, an estimated $46.6M.
  • Ninety One (UK) first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Ninety One (UK)'s Alexion Pharmaceuticals position peaked at $226M in Q1 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Ninety One (UK)'s 13F filing for Q3 2020, filed 12 Nov 2020.